Earnings Feed
Start Free
Ikena Oncology, Inc.·4

Jan 12, 7:25 PM ET

Zhang Xiaoyan Michelle 4

4 · Ikena Oncology, Inc. · Filed Jan 12, 2022

Insider Transaction Report

Form 4
Period: 2022-01-10
Ikena Oncology, Inc.IKNA
Zhang Xiaoyan Michelle
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2022-01-10$2.15/sh+36$77→ 44,511 total
  • Sale

    Common Stock

    [F1]
    2022-01-10$12.00/sh−36$432→ 44,475 total
  • Exercise/Conversion

    Common Stock

    2022-01-11$2.15/sh+964$2,069→ 45,439 total
  • Sale

    Common Stock

    [F1]
    2022-01-11$12.00/sh−964$11,568→ 44,475 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F2]
    2022-01-10−36→ 25,437 total
    Exercise: $2.15Exp: 2028-12-17→ Common Stock (36 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F2]
    2022-01-11−964→ 24,473 total
    Exercise: $2.15Exp: 2028-12-17→ Common Stock (964 underlying)
Footnotes (2)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2021.
  • [F2]25% of the shares subject to this option vested and became exercisable on December 14, 2018, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Signature
/s/ Douglas R. Carlson, as Attorney-in-Fact for Xiaoyan Michelle Zhang|2022-01-12

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION